Strategic Targeting for Optimal Prevention of Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Genetic Testing: Buccal swab
Study summary
The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early detection and treatment of the condition.
Eligibility
Primary outcome measure(s)
- Genomic cancer screen — 120 Days
A study subject is known to have personal and/or family history of cancer known to be influenced by genetic variation. - Genomic cancer screen — 120 Days
A genotype known to be a predisposition for cancer.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Sunbeam Clinical | Prosper | Texas | Recruiting |
More ClinLogic LLC trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03897374 on ClinicalTrials.gov ↗ ← All trials in the USA